The Hippo signaling pathway as a therapeutic target in Alzheimer’s disease - Molecular Neurodegeneration The Hippo signaling pathway is well-known for its regulation of organ size, cell proliferation, apoptosis, and cell migration and differentiation. Recent studies have demonstrated that Hippo signaling also plays important roles in the nervous system, being involved in neuroinflammation, neuronal differentiation, and neuronal death and degeneration. As such, dysregulation of Hippo signaling, particularly of its core kinases MST1/2 and LATS1/2, has begun to attract attention in the Alzheimer’s disease (AD) field. Here, we discuss the therapeutic potential of targeting the Hippo pathway in AD by providing an overview of Hippo signaling with regards to its function in the nervous system, evidence for its dysregulation in AD patients and models, and recent studies involving genetic or pharmacological modulation of this pathway in AD.

The #HippoSignaling pathway as a #therapeutic target in #AlzheimersDisease

Doris Chen, Stella Wigglesworth-Littlewood, Frank J. Gunn-Moore

molecularneurodegeneration.biomedcentral.com/articles/10....

A comprehensive discussion on the #HippoSignaling pathway, its key components, and its relevance in #BreastCancer, with insights on its regulation by #miRNAs and other related pathways. #medsky

#OpenAccess:

Detail of Figure 1: Schematic illustrating the strategy for isolating single nuclei from purified murine glomeruli, with podocyte-specific deletion of YAP or TAZ. UMAP plots show distinct clusters of podocytes.

📣📣📣 Latest news from the NephroLab Cologne – more specifically, from our 🦛 Hippo- Team:
Our snRNA-Seq study on YAP and TAZ in kidney podocytes is now online open access in JASN! 🥳 🎉 🐙
Huge thanks to everyone on the team and the incredibly thorough reviewers at […]

[Original post on social.cologne]